Second malignancies in essential thrombocythemia (ET): A retrospective analysis of 331 patients with long-term follow-up from a single institution

Hematology

Volumn 13, Issue 4, 2008, Pages 195-202

  Radaelli, Franca ^a   Onida, Francesco ^a,b   Rossi, Francesca G ^a   Zilioli, Vittorio R ^a   Colombi, Mariangela ^a   Usardi, Patrizia ^a   Calori, Rossella ^a   Zanella, Alberto ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Alkylating agents; Chemotherapy; Essential thrombocythemia; Hydroxyurea; Secondary malignancies

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CYTOTOXIC AGENT; HYDROXYUREA; MELPHALAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND CANCER; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; BUSULFAN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; HYDROXYUREA; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 55849089046     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453308X316022     Document Type: Article

References (28)

1. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-232.
2. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004; 117(10): 755-761.
3. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 2001; 15(3): 121-131.
4. Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117: 796-808.
5. Cervantes F, Alvarez-Larran A, Talarn C, Gomez M, Montserrat E. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: Actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786-790.
6. Sterkers Y, Preudhomme C, Lai JL et al. Acute myeloid leukemia and myelodysplastic syndromes following Essential Thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998; 91: 616-622.
7. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with Essential Thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 2000; 110: 577-583.
8. Murphy S. Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997; 78(1): 622-626.
9. Finazzi G, Barbui T. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. Pathol Biol (Paris) 2001; 49(2): 167-169.
10. Harrison CN. Current trends in essential thrombocythaemia. Br J Haematol 2002; 117: 796-808.
11. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005; 353(1): 85-86.
12. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential Thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23: 177-82.
13. Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and genetics. Tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC, 2001.
14. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556.
15. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in Essential Thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926- 2930.
16. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representation of old estimators. Stat Med 1999; 18: 695-706.
17. Satagopan JM, Ben-Porat L, Berwick M et al. A note on competing risks in survival data analysis. Br J Cancer 2004; 91: 1229-1235.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 6(3): 1141-1154.
19. Radaelli F, Colombi M, Calori R, Zilioli VR, Bramanti S, Iurlo A, Zanella A. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with Essential Thrombocythemia. Hematol Oncol 2007; 25: 1-6.
20. Radaelli F, Mazza R, Curioni E, Ciani A, Pomati M, Maiolo A-T. Acute megakaryocytic leukaemia in essential thrombocythemia: An unusual evolution? Eur J Haematol 2002; 69: 108-111.
21. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
22. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350(12): 1211- 1219.
23. Barbui T. The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Semin Hematol 2004; 41(2 Suppl 3): 15-17.
24. Passamonti F, Cazzola M. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. Haematologica 2004; 89(11): 1284-1285.
25. Tefferi A. Is hydroxyurea leukemogenic in essential thrombocythemia? Blood 1998; 92: 1459-1460.
26. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with Essential Thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 2002; 116: 923-924.
27. Fruchtman SM, Hoffman R. Essential Thrombocythemia. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds) Hematology: Basic principles and practice, 4th ed. Philadelphia: Churchill Livingstone, 2005; 1277-1296.
28. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Ferneaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analyses of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997; 39: 11-18.